What was the market valuation of the US oral anticoagulants market in 2024?

The market valuation of the US oral anticoagulants market was $5.75 Billion in 2024. Read More

What is the projected market valuation for the US oral anticoagulants market by 2035?

The projected market valuation for the US oral anticoagulants market is $9.55 Billion by 2035. Read More

What is the expected CAGR for the US oral anticoagulants market during the forecast period 2025 - 2035?

The expected CAGR for the US oral anticoagulants market during the forecast period 2025 - 2035 is 4.72%. Read More

Which product segment had the highest valuation in 2024 within the US oral anticoagulants market?

In 2024, the Novel Oral Anticoagulants segment had the highest valuation at $3.45 Billion. Read More

What is the projected valuation for the Warfarin segment by 2035?

The projected valuation for the Warfarin segment is $4.0 Billion by 2035. Read More

Which disease indication segment is expected to grow the most by 2035?

The Heart Attacks disease indication segment is expected to grow the most, reaching $2.15 Billion by 2035. Read More

What was the valuation of the Deep Vein Thrombosis (DVT) segment in 2024?

The valuation of the Deep Vein Thrombosis (DVT) segment was $1.2 Billion in 2024. Read More

Which distribution channel is projected to have the highest growth by 2035?

The Retail Pharmacies distribution channel is projected to have the highest growth, reaching $4.8 Billion by 2035. Read More

Who are the key players in the US oral anticoagulants market?

Key players in the US oral anticoagulants market include Bristol-Myers Squibb, Bayer, Johnson & Johnson, Sanofi, Pfizer, AstraZeneca, Daiichi Sankyo, Roche, and Merck & Co. Read More

What was the valuation of the Online Pharmacies distribution channel in 2024?

The valuation of the Online Pharmacies distribution channel was $1.6 Billion in 2024. Read More

US Oral Anticoagulants Market

ID: MRFR/HC/17936-HCR

100 Pages

Rahul Gotadki

Last Updated: April 24, 2026

US Oral Anticoagulants Market Research Report: Size, Share, Trend Analysis By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Disease Indication (Atrial Fibrillation, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Heart Attacks) and By Product (Novel Oral Anticoagulant, Warfarin) - Growth Outlook & Industry Forecast 2025 To 2035

US Oral Anticoagulants Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Medical Device, BY Product (USD Billion)
  1. 4.1.1 Novel Oral Anticoagulants
  2. 4.1.2 Warfarin
2. 4.2 Medical Device, BY Disease Indication (USD Billion)
  1. 4.2.1 Atrial Fibrillation
  2. 4.2.2 Deep Vein Thrombosis (DVT)
  3. 4.2.3 Pulmonary Embolism (PE)
  4. 4.2.4 Heart Attacks
3. 4.3 Medical Device, BY Distribution Channel (USD Billion)
  1. 4.3.1 Hospital Pharmacies
  2. 4.3.2 Retail Pharmacies
  3. 4.3.3 Online Pharmacies
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Medical Device
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Medical Device
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Bristol-Myers Squibb (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bayer (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Johnson & Johnson (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Sanofi (FR)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Daiichi Sankyo (JP)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Roche (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Merck & Co. (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY PRODUCT
3. 6.3 US MARKET ANALYSIS BY DISEASE INDICATION
4. 6.4 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
5. 6.5 KEY BUYING CRITERIA OF MEDICAL DEVICE
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF MEDICAL DEVICE
8. 6.8 DRIVERS IMPACT ANALYSIS: MEDICAL DEVICE
9. 6.9 RESTRAINTS IMPACT ANALYSIS: MEDICAL DEVICE
10. 6.10 SUPPLY / VALUE CHAIN: MEDICAL DEVICE
11. 6.11 MEDICAL DEVICE, BY PRODUCT, 2024 (% SHARE)
12. 6.12 MEDICAL DEVICE, BY PRODUCT, 2024 TO 2035 (USD Billion)
13. 6.13 MEDICAL DEVICE, BY DISEASE INDICATION, 2024 (% SHARE)
14. 6.14 MEDICAL DEVICE, BY DISEASE INDICATION, 2024 TO 2035 (USD Billion)
15. 6.15 MEDICAL DEVICE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
16. 6.16 MEDICAL DEVICE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY PRODUCT, 2025-2035 (USD Billion)
  2. 7.2.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Medical Device Market Segmentation

Medical Device By Product (USD Billion, 2025-2035)

Novel Oral Anticoagulants
Warfarin

Medical Device By Disease Indication (USD Billion, 2025-2035)

Atrial Fibrillation
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Heart Attacks

Medical Device By Distribution Channel (USD Billion, 2025-2035)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”